Moleculin Biotech Inc

NASDAQ:MBRX   10:07:17 AM EDT
3.42
+0.09 (+2.70%)
Products

Moleculin Announces Successful Completion Of Pre-Ind Meeting With The FDA

Published: 09/09/2020 11:49 GMT
Moleculin Biotech Inc (MBRX) - Moleculin Announces Successful Completion of Pre-ind Meeting With the FDA.
Moleculin Biotech Inc - Intends to File an Ind Using Annamycin for Treatment of Soft Tissue Sarcomas With Lung Metastases by Year-end.
Moleculin Biotech Inc - FDA Did Not Object to Proposed Clinical Study Design.
Moleculin Biotech Inc - FDA Recommended an Eop1 Meeting After Completion of Rp2d.